Citations

Clear

361 citation(s) found for "Bauer, M".

Immunogenetics of lithium response and psychiatric phenotypes in patients with bipolar disorder
Gutiérrez-Fragoso, Karina , Amare, Azmeraw T. , Adli, Mazda , Akiyama, Kazufumi , Akula, Nirmala , Ardau, Raffaella , Arias, Bárbara , Aubry, Jean‐Michel , Benabarre, Antonio , Bengesser, Susanne , Abesh, Bhattacharjee, Birner, Armin , Cearns, Micah , Cervantes, Pablo , Chillotti, Caterina , Cichon, Sven , Clark, Scott R. , Dalkner, Nina , Zompo, Maria Del , Forstner, Andreas J. , Frank, Josef , Frisén, Louise , Frye, Mark A. , Gard, Sébastien, Grof, Paul , Hsu, Yi‐Hsiang , Kahn, Jean‐Pierre, Kassem, Layla, Laje, Gonzalo, Landén, Mikael , Lavebratt, Catharina , Leckband, Susan G. , Maj, Mario , Mitjans, Marina , Mondimore, Francis M. , Nöthen, Markus M. , O’Donovan, Claire , Pisanu, Claudia , Potash, James B. , Richard-Lepouriel, Hélène , Roberts, Gloria , Schalling, Martin , Schweizer, Barbara , Severino, Giovanni , Shekhtman, Tatyana , Shilling, Paul D. , Shimoda, Kazutaka , Simhandl, Christian , Slaney, Claire , Stamm, Thomas , Streit, Fabian , Veeh, Julia, Witt, Stephanie H. , Zandi, Peter P. , Bauer, Michael , Herrera-Rivero, Marisol , Amare, Azmeraw , Arias, Bárbara , Biernacka, Joanna , Cearns, Micah , Chen, Hsi-Chung , Clark, Scott , Cruceanu, Cristiana , Czerski, Piotr , Del Zompo, Maria , DePaulo, J Raymond , Forstner, Andreas J , Frank, Josef , Frye, Mark , Fullerton, Janice M , Garnham, Julie , Grigoroiu-Serbanescu, Maria , Hashimoto, Ryota , Hauser, Joanna , Heilbronner, Urs , Hou, Liping , Hsu, YiHsiang, Jamain, Stéphane , Kelsoe, John R , Kuo, Po-Hsiu , Kusumi, Ichiro , Landén, Mikael , Lavebratt, Catharina , Leboyer, Marion , Marie-Claire, Cynthia , Nievergelt, Caroline M , Novak, Tomas , Nöthen, Markus M , Ozaki, Norio , Papiol, Sergi , Pisanu, Claudia , Reif, Andreas , Reininghaus, Eva , Rouleau, Guy Armand , Rybakowski, Janusz K , Schalling, Martin , Schofield, Peter R , Schubert, Klaus Oliver , Schulte, Eva , Severino, Giovanni , Shimoda, Kazutaka , Squassina, Alessio , Streit, Fabian , Turecki, Gustavo , Vieta, E , Viswanath, Biju , Witt, Stephanie H , Alda, Martin , Bauer, M , McMahon, Francis , Mitchell, Philip B , Rietschel, Marcella , Schulze, Thomas , Cichon, Sven , Mitjans, Marina , Thalamuthu, Anbupalam , Backlund, Lena , Bellivier, Frank , Biernacka, Joanna M. , Chen, Hsi‐Chung , Colom, Francesc , Cruceanu, Cristiana , Czerski, Piotr M. , Dalkner, Nina , Degenhardt, Franziska , Étain, Bruno , Falkai, Peter , Ferensztajn‐Rochowiak, Ewa , Fullerton, Janice M. , Gallo, Carla , Goes, Fernando , Grigoroiu‐Serbânescu, Maria , Hashimoto, Ryota , Hasler, Roland , Heilbronner, Urs , Herms, Stefan , Hoffmann, Per , Jamain, Stéphane , Jiménez, Esther , Kato, Tadafumi , Kittel‐Schneider, Sarah , Kuo, Po‐Hsiu , Kurtz, Joachim , König, Barbara , Leboyer, Marion , Manchia, Mirko , Martinsson, Lina , McCarthy, Michael J. , McElroy, Susan L. , Millischer, Vincent , Monteleone, Palmiero , Novák, Tomáš , Ozaki, Norio , Papiol, Sergi , Pfennig, Andrea , Reif, Andreas , Schofield, Peter R. , Schubert, Klaus Oliver , Schulte, Eva C. , Squassina, Alessio , Stopková, Pavla , Tekola‐Ayele, Fasil , Tortorella, Alfonso , Turecki, Gustavo , Vieta, Eduard , Viswanath, Biju , Alda, Martin , McMahon, Francis J. , Baune, Bernhard

Mayo Clinic

No container title available | June 26, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3068352/v1 | PMID 37461719 Get It

Abstract The link between bipolar disorder (BP) and immune dysfunction remains controversial. While epidemiological studies have long suggested an association, recent research has found only limited evidence of such a relationship. To clarify this, we investigated the contributions of immune-relevant genetic factors to the response to lithium (Li) treatment and the clinical presentation of BP. First, we assessed the association of a large collection of immune-related genes (4,925) with Li response, defined by the Retrospective Assessment of the Lithium Response Phenotype Scale (Alda scale), and clinical characteristics in patients with BP from the International Consortium on Lithium Genetics (ConLi+Gen, N = 2,374). Second, we calculated here previously published polygenic scores (PGSs) for immune-related traits and evaluated their associations with Li response and clinical features. We found several genes associated with Li response at p < 1x10− 4 values, including HAS3, CNTNAP5 and NFIB. Network and functional enrichment analyses uncovered an overrepresentation of pathways involved in cell adhesion and intercellular communication, which appear to converge on the well-known Li-induced inhibition of GSK-3β. We also found various genes associated with BP’s age-at-onset, number of mood episodes, and presence of psychosis, substance abuse and/or suicidal ideation at the exploratory threshold. These included RTN4, XKR4, NRXN1, NRG1/3 and GRK5. Additionally, PGS analyses suggested serum FAS, ECP, TRANCE and cytokine ligands, amongst others, might represent potential circulating biomarkers of Li response and clinical presentation. Taken together, our results support the notion of a relatively weak association between immunity and clinically relevant features of BP at the genetic level.
In Vivo Emergence of Dual Resistance to Rifampin and Levofloxacin in Osteoarticular Cutibacterium avidum
Woerther, Paul‐Louis , Ménigaux, C., Herrmann, Jean‐Louis , Rottman, Martin , Roux, Anne‐Laure , Gaillard, Jean-Louis , Patel, Robin , Woerther, Paul-Louis , Rottman, Martin , Patel, Robin , El Sayed, Faten , Cunningham, Scott A. , Rodriguez, Christophe , Bauer, Thomas W.

Mayo Clinic

Microbiology Spectrum | June 8, 2023 | Volume: 11 | Issue: 4 | Pages: No page available

10.1128/spectrum.03687-22 | PMID 37289061 Get It

In this study, we report for the first time the in vivo emergence of dual resistance to levofloxacin and rifampin in C. avidum isolated from a patient who received both antibiotics orally in the setting of a salvage debridement and implant retention of an ODRI. Aside from the molecular insights reported here, this study highlights potential limitations of the combination of oral rifampin and levofloxacin in patients undergoing these surgical procedures and the potential need to evaluate specific optimal therapy for emerging ODRI pathogens.
Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study.
Schöffski, Patrick , Razak, Albiruni Ryan Abdul, Attia, Steven , Cesne, Axel Le, Sprott, Kam , Achour, Haroun, Sherman, Matthew L. , Ruiz‐Soto, Rodrigo , Investigators, on behalf of the INTRIGUE, Trent, Jonathan C. , Jones, Robin L. , George, Suzanne , Gelderblom, Hans , Mehren, Margaret von , Zalcberg, John , Kang, Yoon‐Koo , Cesne, Axel Le , Reichmann, William M. , Blay, Jean‐Yves , Heinrich, Michael C. , Bauer, Sebastian , Investigators, on behalf of the INTRIGUE

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 11536-11536

10.1200/jco.2023.41.16_suppl.11536 Get It

11536 Background: Ripretinib is a switch-control tyrosine kinase inhibitor approved for patients (pts) with gastrointestinal stromal tumor (GIST) who received prior treatment with ≥3 kinase inhibitors, including imatinib. Exploratory baseline circulating tumor DNA (ctDNA) next-generation sequencing (NGS) analysis from INTRIGUE showed pts with second-line advanced GIST with primary KIT exon 11 mutations and secondary resistance mutations exclusively in KIT exons 17/18 derived clinical benefit from ripretinib but not sunitinib (Bauer S et al. J Clin Oncol. 2023; Abs 397784). Outcomes in pts with advanced GIST with ctDNA not detected (ctDNA-ND) had not been evaluated. Here, we present exploratory data from INTRIGUE in pts who had baseline ctDNA-ND vs ctDNA detected (ctDNA-D). Methods: INTRIGUE is an open-label, phase 3 study that enrolled pts with advanced GIST who had disease progression on or intolerance to imatinib (NCT03673501). Pts were randomized 1:1 to ripretinib 150 mg once daily (QD) or sunitinib 50 mg QD (4 wks on/2 wks off) and stratified by mutation according to local pathology report. Baseline peripheral whole blood was analyzed by Guardant360, a 74-gene ctDNA NGS-based assay. Pts with ctDNA-D had ≥1 somatic alteration in the 74 genes analyzed. Results: Pts with ctDNA-ND (82/362, 22.7%) were younger (median: 55.5 vs 62.0 years) and had smaller sums of longest diameters of target lesions (median [range]: 57.6 [11–459] vs 108.8 [15–418] mm) vs ctDNA-D (280/362, 77.3%). Progression-free survival (PFS) was longer in pts with ctDNA-ND vs ctDNA-D and numerically higher with ripretinib vs sunitinib in pts with ctDNA-ND (Table). Pts with ctDNA-ND categorized as not having a KIT exon 9 mutation at randomization ( KIT exon 11, other KIT/PDGFRA, or KIT/PDGFRA wild-type; n = 71) had longer PFS with ripretinib vs sunitinib (median not estimable [NE] vs 11 months; HR = 0.56; 95% CI 0.28 to 1.12). Objective response rate (ORR) and overall survival (OS) were higher with ctDNA-ND vs ctDNA-D. Safety was similar between groups and consistent with the primary analysis. Conclusions: Pts with ctDNA-ND had better efficacy outcomes vs pts with ctDNA-D in both treatment arms; PFS was numerically higher with ripretinib vs sunitinib in pts with ctDNA-ND. Although little is known about the biology driving ctDNA in GIST, these data suggest pts may have improved outcomes and different treatment sensitivity based on ctDNA detectability. Clinical trial information: NCT03673501 . [Table: see text]
Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.
Schöffski, Patrick , Razak, Albiruni Ryan Abdul, Attia, Steven , Cesne, Axel Le , Achour, Haroun, Sherman, Matthew L. , Ruiz‐Soto, Rodrigo , Investigators, on behalf of the INTRIGUE, Jones, Robin L. , Blay, Jean‐Yves , George, Suzanne , Gelderblom, Hans , Mehren, Margaret von , Zalcberg, John , Kang, Yoon‐Koo , Trent, Jonathan C. , Reichmann, William M. , Bauer, Sebastian , Heinrich, Michael C. , Investigators, on behalf of the INTRIGUE

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 11524-11524

10.1200/jco.2023.41.16_suppl.11524 Get It

11524 Background: Ripretinib is a switch-control tyrosine kinase inhibitor approved for patients (pts) with gastrointestinal stromal tumor (GIST) who received prior treatment with ≥3 kinase inhibitors, including imatinib. Sunitinib is approved for advanced GIST after imatinib failure. In the first interim analysis (IA) for overall survival (OS) in the INTRIGUE trial, data were immature (OS event rate, 22.3%), and median OS was not reached in either arm for the KIT exon 11 intent-to-treat (ITT) and all-patient (AP) ITT populations (S Bauer, et al. J Clin Oncol. 2022). Additionally, ripretinib had a more favorable safety profile with fewer grade 3/4 treatment-emergent adverse events (TEAEs) than sunitinib. Here, we present the second IA of OS and updated safety from INTRIGUE. Methods: INTRIGUE is a global, open-label, phase 3 study that enrolled adult pts with advanced GIST who had disease progression on or intolerance to imatinib (NCT03673501). Randomization was 1:1 to ripretinib 150 mg once daily (QD) or sunitinib 50 mg QD (4 wks on/2 wks off) and was stratified by KIT mutational status and imatinib intolerance. OS was a key secondary endpoint; data cutoff for the second IA was Sept 1, 2022. Results: Of 453 pts in the AP ITT population, 444 received treatment; 51 remain on treatment (33/223 [14.8%] with ripretinib and 18/221 [8.1%] with sunitinib). Common reasons for treatment discontinuation were progressive disease (PD) assessed by independent radiologic review (55.4%), PD assessed by investigator (10.6%), clinical PD (5.9%), withdrawal of consent (5.4%), and adverse event (AE; 4.5%); fewer pts discontinued due to an AE for ripretinib vs sunitinib (2.7% vs 6.3%). Following study treatment discontinuation, 58 pts (25.6%) from the sunitinib arm received ripretinib; 139 pts (61.5%) from the ripretinib arm later received sunitinib. There were 185 OS events (40.8%) in the AP ITT population; median duration of follow-up was 28.7 and 28.5 months for ripretinib and sunitinib, respectively. OS was similar with ripretinib vs sunitinib in the AP ITT (median 35.5 vs 30.9 months; HR 0.88, 95% CI 0.66 to 1.18; nominal P = 0.39) and KIT exon 11 ITT populations (median 34.0 vs 31.5 months; HR 1.05, 95% CI 0.75 to 1.48; nominal P = 0.77). The updated safety profile was consistent with the primary analysis; fewer pts had grade 3/4 TEAEs with ripretinib vs sunitinib (95 [42.6%] vs 149 [67.4%]). Dose interruptions and reductions were lower with ripretinib vs sunitinib. The median (range) treatment duration was 7.9 (0.2–38.2) months for ripretinib and 6.5 (0.2–38.3) months for sunitinib. Conclusions: In the second IA from INTRIGUE, OS was similar between treatment arms. The safety profile remained consistent with additional data, and results demonstrate favorable safety with ripretinib in pts with advanced GIST previously treated with imatinib. Clinical trial information: NCT03673501 .
Low Tidal Volume Strategy: What Else?*
Puentes, G.A. Cortes, Bauer, Philippe R.

Mayo Clinic

Critical Care Medicine | May 18, 2023 | Volume: 51 | Issue: 6 | Pages: 838-841

10.1097/ccm.0000000000005868 | PMID 37199554 Get It

Outcomes of Acute Respiratory Failure in Patients With Cancer in the United States
Deng, Jiawen , Bhandarkar, Archis R. , Zhou, Fangwen , Zamanian, Cameron , Arya, Narshima, Bydon, Mohamad , Walkey, A.J., Yadav, Hemang , Deng, J , Zhou, F , Heybati, Kiyan , Bauer, Philippe R. , Gajic, Ognjen

Mayo Clinic

B23. ADVANCING THE SCIENCE OF ACUTE RESPIRATORY FAILURE | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A2870-A2870

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2870 Get It

Clinical outcome measures reporting in randomized trials evaluating Tuina therapy for chronic nonspecific low back pain: A systematic review
Zhou, Xuan , Ma, Qingyu , Yang, Juan , Mohabbat, Arya B. , Croghan, Ivana T. , Tan, Celia la choo, Chen, Jiaxu , Bauer, Brent A.

Mayo Clinic

Medicine | April 21, 2023 | Volume: 102 | Issue: 16 | Pages: e33628

10.1097/md.0000000000033628 | PMID 37083789 Get It

Background: Tuina has gained widespread attention and utilization for the management of chronic nonspecific low back pain (CNLBP). However, evidence-based guidance for choosing accurate and appropriate outcome measures of Tuina is lacking. The objective of this study is to systematically synthesize the existing outcome measures reported in randomized controlled trials (RCTs) evaluating Tuina therapy in CNLBP. Methods: Electronic literature searches were conducted in multiple English and Chinese databases from their inception to May 2022. RCTs were included if they involved clinical outcome measures in Tuina treatment for patients with CNLBP. Outcome instruments for each study were extracted and analyzed. Evidence from included studies were assessed using the Cochrane risk-of-bias tool. Results: Of the 735 identified articles, 17 articles with 1628 participants were included. Measurement domains in these RCTs were mainly reported in terms of pain (94%) and physical activity (71%), followed by safety (41%), Chinese medicine outcome (35%), and quality of life (12%). Moreover, several limitations with existing outcomes were reported, including lack of emphasis on the evaluation of quality of life, inadequate safety monitoring, as well as insufficient and vague Chinese medicine outcome measures. All trials were deemed to be of poor methodological quality. Conclusion: Pain and physical disability were the most frequently studied outcome domains in CNLBP treated by Tuina therapy. More rigorous and high-quality trials with appropriately selected outcome measures are needed in the future.
Etiologies and Outcome of Patients with Solid Tumors Admitted to ICU with Acute Respiratory Failure: A Secondary Analysis of the EFRAIM Study
Benguerfi, Soraya , Soares, Márcio , Meert, Anne‐Pascale , Martín‐Loeches, Ignacio , Mehta, Sangeeta , Burghi, Gastón, Kouatchet, Achille, Mokart, Djamel, Louw, Andry Van de , Lemiale, Virginie , group, on behalf of the EFRAIM investigators and Nine-I study, Bauer, Philippe, Martin-Loeches, Ignacio , Dumas, Guillaume , Pène, Frédéric , Bauer, Philippe R. , Metaxa, Victoria , Montini, Luca , Mokart, Djamel , Azoulay, Élie , group, on behalf of the EFRAIM investigators and Nine-I study

Mayo Clinic

Respiratory Care | April 18, 2023 | Volume: 68 | Issue: 6 | Pages: 740-748

10.4187/respcare.10604 | PMID 37072164 Get It

BACKGROUND: Acute respiratory failure (ARF) remains the most frequent reason for ICU admission in patients who are immunocompromised. This study reports etiologies and outcomes of ARF in subjects with solid tumors. METHODS: This study was a post hoc analysis of the EFRAIM study, a prospective multinational cohort study that included 1611 subjects who were immunocompromised and with ARF admitted to the ICU. Subjects with solid tumors admitted to the ICU with ARF were included in the analysis. RESULTS: Among the subjects from the EFRAIM cohort, 529 subjects with solid tumors (32.8%) were included in the analysis. At ICU admission, the median (interquartile range) Sequential Organ Failure Assessment score was 5 (3–9). The types of solid tumor were mostly lung cancer ( n = 111, 21%), breast cancer ( n = 52, 9.8%), and digestive cancer ( n = 47, 8.9%). A majority, 379 subjects (71.6%) were full code at ICU admission. The ARF was caused by bacterial or viral infection ( n = 220, 41.6%), extrapulmonary sepsis ( n = 62, 11.7%), or related to cancer or treatment toxicity ( n = 83, 15.7%), or fungal infection ( n = 23, 4.3%). For 63 subjects (11.9%), the ARF etiology remained unknown after an extensive diagnostic workup. The hospital mortality rate was 45.7% ( n = 232/508). Hospital mortality was independently associated with chronic cardiac failure (odds ratio 1.78, 95% CI 1.09–2.92; P = .02), lung cancer (odds ratio 2.50, 95% CI 1.51–4.19; P < .001), day 1 Sequential Organ Failure Assessment score (odds ratio 1.97, 95% CI 1.32-2.96; P < .001). ARF etiologies other than infectious, related to cancer, or treatment toxicity were associated with better outcomes (odds ratio 0.32, 95% CI 0.16–0.61; P < .001). CONCLUSIONS: Infectious diseases remained the most frequent cause of ARF in subjects with solid tumors admitted to the ICU. Hospital mortality was related to severity at ICU admission, previous comorbidities, and ARF etiologies related to non-malignant causes or pulmonary embolism. Lung tumor was also independently associated with higher mortality.
Mindfulness Using a Wearable Brain Sensing Device for Health Care Professionals During a Pandemic: A Pilot Program
Ghosh, Karthik, Nanda, S. , Schroeder, Darrell R. , Bauer, Brent A. , Fokken, Shawn C. , Ganesh, Ravindra , Hanson, Jennifer L., Lindeen, Stephanie A. , Pruthi, Sandhya , Croghan, Ivana T. , Hurt, Ryan T. , Ganesh, Ravindra , Lindeen, Stephanie A , Croghan, Ivana T , Schroeder, Darrell , West, Colin P. , Fischer, Karen M.

Mayo Clinic

Journal of Primary Care & Community Health | March 24, 2023 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/21501319231162308 | PMID 36960553 Get It

Objective: The purpose of this feasibility pilot study was to evaluate safety and adherence of a wearable brain sensing wellness device designed to reduce stress among healthcare professionals (HCP). Methods: A total of 40 HCP were invited to participate in an open-label pilot study. Participants were asked to use a brain sensing wearable device (MUSE-S™) on a daily basis to reduce their stress, for a total of 90 days. Total study participation duration was 180 days. Study enrollment began in August 2021 and ended December 2021. The exploratory outcomes included stress, depression, sleep, burn-out, resilience, quality of life, and cognition. Results: Among the 40 HCP in study, the majority were female (85%), white (87.5%) and with an average age of 41.3 ± 11.0 years (SD). Participants used the wearable device an average of 23.8 times over a 30-day period with a mean duration of 5.8 min with each use. Study results demonstrate the positive impact of guided mindfulness using the wearable device MUSE-S™ and its accompanying application (APP). A statistically significant improvement was found for a reduction in stress ( P < .001) and improvement in resilience ( P = .02), quality of life ( P = .003), and cognition ( P < .001). The majority (91.9%) of the participants indicated they felt more relaxed after using the device, and 73% indicated they would continue to use this device at end-of-study. No adverse effects were reported. Conclusion: Study results show that 3 to 10 min of guided meditation during work hours through the use of a brain sensing wearable device is safe and acceptable, with associated health benefits for HCP.
Efficacy and safety of Tuina for chronic nonspecific low back pain: A PRISMA-compliant systematic review and meta-analysis
Yang, Juan , Zhou, Xuan , Ma, Qingyu , Woods, Jeffrey , Mohabbat, Arya B. , Do, Alexander , Brault, Jeffrey S. , Jensen, Mark A. , Shin, Kyung-Min , Shen, Longbin , Zhao, Canghuan , Cheong, Philip , He, Kejie , Guo, Yu , Chen, Zhuoming , Tang, Yong , Tan, Celia Ia Choo , Bauer, Brent A. , Woods, Jeffrey T., Tang, Shujie , Chen, Jiaxu

Mayo Clinic

Medicine | March 2, 2023 | Volume: 102 | Issue: 9 | Pages: e33018

10.1097/md.0000000000033018 | PMID 36862888 Get It

Objective: Chronic nonspecific low back pain (CNLBP) is a serious medical and social problem resulting in functional decline and decreased work ability. Tuina, a form of manual therapy, has been sparsely used to treat patients with CNLBP. To systematically assess the efficacy and safety of Tuina for patients with CNLBP. Methods: Multiple English and Chinese literature databases were searched until September 2022 for randomized controlled trials (RCTs) of Tuina in the treatment of CNLBP. The methodological quality was assessed using the Cochrane Collaboration’s tool, and certainty of the evidence was determined with the online Grading of Recommendations, Assessment, Development and Evaluation tool. Results: Fifteen RCTs with 1390 patients were included. Tuina demonstrated a significant effect on pain (SMD: −0.82; 95% CI −1.12 to −0.53; P < .001; I 2 = 81%) and physical function (SMD: −0.91; 95% CI −1.55 to −0.27; P = .005; I 2 = 90%) when compared to control. However, Tuina resulted in no significant improvement for quality of life (QoL) (SMD: 0.58; 95% CI −0.04 to 1.21; P = .07; I 2 = 73%;) compared to control. The Grading of Recommendations, Assessment, Development and Evaluation evidence quality was determined to be low level for pain relief, physical function, and QoL measurements. Only six studies reported adverse events; none were serious. Conclusion: Tuina might be an effective and safe strategy for treating CNLBP in terms of pain and physical function, but not for QoL. The study results should be interpreted with caution for their low-level evidence. More multicenter, large-scale RCTs with a rigorous design are required to further confirm our findings.